AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.
AstraZeneca is set to pay Dizal Pharmaceutical, which it part-owns, $600 million upfront for worldwide development and sales rights to the lung cancer drug Zegfrovy.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
Abbisko and AstraZeneca will jointly develop a Phase 1/2 NSCLC therapy combining lumipodlin with Tagrisso after China's IND…
A farmacêutica anunciou um acordo de licenciamento global exclusivo com a chinesa Dizal Pharmaceutical para o Zegfrovy,…
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
